Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study of Brenipatide (LY3537031) Comparing Two Formulations in Healthy Adults

4 de noviembre de 2026 actualizado por: Chamika Hawkins-Taylor, Xavier University of Louisiana.

A Phase 1, Open-Label, Randomized, Crossover, Bioequivalence Study to Compare the Pharmacokinetics of Two Different Formulations of Brenipatide (LY3537031) Administered Via Pre-filled Syringe, in Healthy Participants

The SOLE PURPOSE PILOT will be implemented in participating African Methodist Episcopal (AME) churches in Louisiana using a community-based approach that integrates structured education, standardized foot risk assessment, and facilitated clinical referral.

Eligible participants will provide informed consent and complete baseline assessments addressing demographic characteristics, diabetes history, foot health knowledge, self-care practices, perceived risk, and self-efficacy. Participants will undergo a standardized foot risk assessment that may include visual inspection for ulcers, calluses, deformities, and other abnormalities; sensory testing using a monofilament; pedal pulse assessment; ankle-brachial index measurement when indicated; and evaluation of footwear and relevant clinical history. Screening findings will be documented using standardized data collection instruments.

The educational intervention will consist of three interactive sessions delivered over a 4- to 6-week period. Sessions will address: (1) recognition of diabetes-related foot complications and individual risk factors; (2) daily foot self-examination, preventive self-care, and appropriate footwear; and (3) recognition of warning signs requiring prompt medical attention, healthcare navigation, and self-advocacy. Educational activities will incorporate culturally relevant examples, demonstrations, and opportunities for participants to practice foot care skills.

Participants with screening findings indicating the need for additional clinical evaluation will receive facilitated referrals through a coordinated patient navigation process. Referral urgency will be determined by the clinical findings and established referral procedures. Patient navigators will assist with care coordination, appointment scheduling, identification of barriers to care, and follow-up to document referral outcomes.

Participants will be followed for three months after enrollment. Follow-up assessments will document completion of recommended foot evaluations, changes in foot health knowledge and self-care behaviors, self-efficacy, and referral outcomes. Implementation measures will include recruitment and participation, intervention delivery, fidelity to study procedures, participant acceptability, and adoption within participating church settings.

Study data will be collected using standardized instruments and managed according to approved institutional research procedures. Descriptive analyses will characterize participant demographics, baseline foot risk, intervention participation, screening findings, and referral outcomes. Exploratory analyses will examine changes in participant-reported measures and the proportion completing recommended clinical evaluations. Implementation findings will be used to identify operational barriers, facilitators, and considerations for future program refinement and scale-up.

Descripción general del estudio

Descripción detallada

The SOLE PURPOSE PILOT will be implemented in participating African Methodist Episcopal (AME) churches in Louisiana using a community-based approach that integrates structured education, standardized foot risk assessment, and facilitated clinical referral.

Eligible participants will provide informed consent and complete baseline assessments addressing demographic characteristics, diabetes history, foot health knowledge, self-care practices, perceived risk, and self-efficacy. Participants will undergo a standardized foot risk assessment that includes visual inspection for ulcers, calluses, deformities, and other abnormalities; sensory testing using a monofilament; pedal pulse assessment; ankle-brachial index measurement when indicated; and evaluation of footwear and relevant clinical history. Screening findings will be documented using standardized data collection instruments.

The educational intervention will consist of three interactive sessions delivered over a 4- to 6-week period. Sessions will address: (1) recognition of diabetes-related foot complications and individual risk factors; (2) daily foot self-examination, preventive self-care, and appropriate footwear; and (3) recognition of warning signs requiring prompt medical attention, healthcare navigation, and self-advocacy. Educational activities will incorporate culturally relevant examples, demonstrations, and opportunities for participants to practice foot care skills.

Participants with screening findings indicating the need for additional clinical evaluation will receive facilitated referrals through a coordinated patient navigation process. Referral urgency will be determined by the clinical findings and established referral procedures. Patient navigators will assist with care coordination, appointment scheduling, identification of barriers to care, and follow-up to document referral outcomes.

Participants will be followed for three months after enrollment. Follow-up assessments will document completion of recommended foot evaluations, changes in foot health knowledge and self-care behaviors, self-efficacy, and referral outcomes. Implementation measures will include recruitment and participation, intervention delivery, fidelity to study procedures, participant acceptability, and adoption within participating church settings.

Study data will be collected using standardized instruments and managed according to approved institutional research procedures. Descriptive analyses will characterize participant demographics, baseline foot risk, intervention participation, screening findings, and referral outcomes. Exploratory analyses will examine changes in participant-reported measures and the proportion completing recommended clinical evaluations. Implementation findings will be used to identify operational barriers, facilitators, and considerations for future program refinement and scale-up.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

180

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Chamika Hawkins-Taylor, PhD, MHA
  • Número de teléfono: 504-520-5363
  • Correo electrónico: chawkin5@xula.edu

Copia de seguridad de contactos de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:Self-identifies as Black or African American. Aged 18 years or older. Has a self-reported or clinically documented diagnosis of diabetes mellitus (Type 1 or Type 2).

Resides in Louisiana or receives healthcare services in Louisiana.

Meets at least one of the following elevated foot-risk criteria:

Previous diabetic foot ulcer or lower extremity amputation. Self-reported symptoms of peripheral neuropathy, including numbness, tingling, or burning sensations in the feet.

Current or recent foot callus, deformity, lesion, or other foot abnormality. Insulin use or diabetes duration of 10 years or longer. Known chronic kidney disease, peripheral artery disease, or previous diabetes-related hospitalization.

Current or recent tobacco smoking. Able and willing to provide informed consent. Willing to participate in the church-based educational intervention, foot risk screening, and follow-up assessments.

Exclusion Criteria:

Younger than 18 years of age. No diagnosis of diabetes mellitus. Does not meet any of the specified elevated foot-risk criteria. Unable to provide informed consent. Unwilling or unable to participate in the study intervention or required follow-up assessments.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Poner en pantalla
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: SOLE PURPOSE Foot Health Intervention

Participants assigned to this single-arm intervention will receive a culturally tailored, church-based foot health program delivered over 4-6 weeks. The program includes three structured educational sessions addressing diabetes-related foot complications, preventive foot care, recognition of warning signs, and healthcare navigation. Participants will also receive standardized foot risk screening, including sensory and vascular assessments when indicated, and facilitated referral to appropriate clinical services based on screening findings. Patient navigation will support referral coordination and follow-up. Participants will be assessed for completion of guideline-concordant foot evaluations within three months of enrollment.

A culturally tailored, church-based intervention integrating structured foot health education, standardized foot risk screening, and facilitated clinical referral for Black adults with diabetes. The intervention includes three interactive educational sessions delivered over 4-6 weeks covering diabetes-related foot complications, daily foot self-examination, preventive care, recognition of warning signs, and healthcare navigation. Participants undergo foot risk screening, including visual inspection, sensory testing, pedal pulse assessment, and ankle-brachial index measurement when indicated. Individuals requiring additional evaluation receive facilitated referrals supported by patient navigation, including care coordination and follow-up to assess completion of recommended foot evaluations.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of Participants Completing a Guideline-Concordant Foot Evaluation
Periodo de tiempo: Within 3 months of baseline screening

The proportion of enrolled participants who complete a guideline-concordant foot evaluation within three months of baseline screening. A qualifying evaluation includes a podiatry visit, comprehensive primary care diabetic foot examination with documented risk stratification, wound clinic visit, or vascular evaluation when clinically indicated. Completion will be determined through participant self-report, referral tracking logs, and medical record confirmation when available. The outcome will be calculated as the number of participants completing a qualifying evaluation divided by the total number of enrolled participants, expressed as a percentage.

Within 3 months of baseline screening

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Foot Health Literacy and Knowledge Scores
Periodo de tiempo: Baseline, immediately post-intervention, and 3 months after baseline.

Change in foot health knowledge will be measured using a study-specific questionnaire assessing recognition of diabetic foot warning signs, appropriate care-seeking, daily foot self-examination, preventive footwear practices, and common misconceptions. Scores will be compared across assessment time points, with higher scores indicating greater knowledge.

Baseline, immediately post-intervention, and 3 months after baseline.
Change in Foot Self-Care Behavior Score
Periodo de tiempo: Baseline and 3 months after baseline

Change in foot self-care behaviors will be assessed using the foot-care subscale of the Summary of Diabetes Self-Care Activities (SDSCA) questionnaire or an equivalent measure. Behaviors assessed include daily foot inspection, appropriate footwear use, avoidance of walking barefoot, and timely reporting of foot problems. Scores will be compared between baseline and three-month follow-up, with higher scores indicating greater adherence to recommended foot self-care practices.

Baseline and 3 months after baseline
Proportion of Participants Completing Foot Risk Screening
Periodo de tiempo: Baseline (at enrollment)

The proportion of enrolled participants who complete a standardized baseline foot risk assessment at a participating church event or linked clinical site. Screening completion will be documented using study assessment records. The measure will be calculated as the number of participants completing the assessment divided by the total number enrolled, expressed as a percentage.

Baseline (at enrollment)
Referral Completion Rate Among Participants Requiring Follow-Up
Periodo de tiempo: Within 3 months of baseline screening

Among participants classified as Tier 2 or Tier 3 based on standardized foot risk screening and referred for additional clinical evaluation, the proportion who complete the recommended evaluation within three months of baseline screening. Referral completion will be assessed using patient navigation records, participant self-report, and clinical documentation when available. The denominator will include all participants receiving a qualifying referral.

Within 3 months of baseline screening
Change in Foot Care Self-Efficacy Score
Periodo de tiempo: Baseline, immediately post-intervention, and 3 months after baseline

Change in participants' confidence in performing daily foot self-examinations, recognizing warning signs, and seeking appropriate professional care will be assessed using study-specific Likert-scale items or a validated self-efficacy instrument. Scores will be compared at baseline, immediately following the educational intervention, and at three-month follow-up. Higher scores will indicate greater confidence in managing foot health.

Baseline, immediately post-intervention, and 3 months after baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Chamika Hawkins-Taylor, PhD, MHA, Xavier University of Louisiana.
  • Investigador principal: Rene Hymel, DPM, CWSP, Foot Health Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

7 de noviembre de 2026

Finalización primaria (Estimado)

27 de noviembre de 2027

Finalización del estudio (Estimado)

27 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

4 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Publicado por primera vez (Actual)

10 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 27981
  • 001 (Otro número de subvención/financiamiento: Louisiana Health Care Connection)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir